01O Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a post hoc analysis.

MLA

Vissing, J., et al. “01O Response to Rozanolixizumab across Treatment Cycles in Patients with Generalised Myasthenia Gravis: A Post Hoc Analysis.” Neuromuscular Disorders, vol. 43, Oct. 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.nmd.2024.07.012.

APA

Vissing, J., Grosskreutz, J., Habib, A., Mahuwala, Z., Mantegazza, R., Pascuzzi, R., Sacconi, S., Vu, T., Beau Lejdstrom, R., Greve, B., Grimson, F., Tarancón, T., & Bril, V. (2024). 01O Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a post hoc analysis. Neuromuscular Disorders, 43, N.PAG. https://doi.org/10.1016/j.nmd.2024.07.012

Chicago

Vissing, J., J. Grosskreutz, A. Habib, Z. Mahuwala, R. Mantegazza, R. Pascuzzi, S. Sacconi, et al. 2024. “01O Response to Rozanolixizumab across Treatment Cycles in Patients with Generalised Myasthenia Gravis: A Post Hoc Analysis.” Neuromuscular Disorders 43 (October): N.PAG. doi:10.1016/j.nmd.2024.07.012.